{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:03:58Z","timestamp":1767143038534,"version":"build-2238731810"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s42000-018-0077-6","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T09:32:23Z","timestamp":1542187943000},"page":"531-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Conducting an observational study during an economic crisis: analysis of the treatment and follow-up phase of Greek patients participating in the ExFOS study"],"prefix":"10.1007","volume":"17","author":[{"name":"for the Greek ExFOS study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0442-6231","authenticated-orcid":false,"given":"Kyriakos","family":"Aloumanis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Kapetanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Alexandridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Drossinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,14]]},"reference":[{"issue":"8","key":"77_CR1","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1210\/jc.2012-1262","volume":"97","author":"DW Dempster","year":"2012","unstructured":"Dempster DW, Zhou H, Recker RR et al (2012) Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. J Clin Endocrinol Metab 97(8):2799\u20132808","journal-title":"J Clin Endocrinol Metab"},{"key":"77_CR2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.bone.2014.07.014","volume":"67","author":"EF Eriksen","year":"2014","unstructured":"Eriksen EF, Keaveny TM, Gallagher ER, Krege JH (2014) Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 67:246\u2013256","journal-title":"Bone"},{"issue":"6","key":"77_CR3","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1210\/jc.2011-3060","volume":"97","author":"MH Murad","year":"2012","unstructured":"Murad MH, Drake MT, Mullan RJ et al (2012) Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871\u20131880","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"77_CR4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u221234) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 10 344(19):1434\u20131441","journal-title":"N Engl J Med 10"},{"key":"77_CR5","doi-asserted-by":"crossref","unstructured":"Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230\u2013240","DOI":"10.1016\/S0140-6736(17)32137-2"},{"issue":"6","key":"77_CR6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2146\/ajhp070171","volume":"65","author":"J Stroup","year":"2008","unstructured":"Stroup J, Kane MP, Abu-Baker AM (2008) Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 15 65(6):532\u2013539","journal-title":"Am J Health Syst Pharm 15"},{"issue":"8","key":"77_CR7","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1007\/s00198-016-3534-6","volume":"27","author":"R Lindsay","year":"2016","unstructured":"Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ (2016) Teriparatide for osteoporosis: importance of the full course. Osteoporosis Int 27(8):2395\u20132410","journal-title":"Osteoporosis Int"},{"issue":"7040","key":"77_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/bmj.312.7040.1215","volume":"312","author":"N Black","year":"1996","unstructured":"Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 11 312(7040):1215\u20131218","journal-title":"BMJ 11"},{"issue":"4","key":"77_CR9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00198-007-0488-8","volume":"19","author":"C Cooper","year":"2008","unstructured":"Cooper C, Jakob F, Chinn C et al (2008) Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporosis Int 19(4):493\u2013501","journal-title":"Osteoporosis Int"},{"issue":"8","key":"77_CR10","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00198-013-2284-y","volume":"24","author":"S Silverman","year":"2013","unstructured":"Silverman S, Miller P, Sebba A et al (2013) The direct assessment of nonvertebral fractures in community experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporosis Int 24(8):2309\u20132317","journal-title":"Osteoporosis Int"},{"issue":"10","key":"77_CR11","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s00198-010-1498-5","volume":"22","author":"A Fahrleitner-Pammer","year":"2011","unstructured":"Fahrleitner-Pammer A, Langdahl BL, Marin F et al (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporosis Int 22(10):2709\u20132719","journal-title":"Osteoporosis Int"},{"issue":"8","key":"77_CR12","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1185\/03007995.2014.907561","volume":"30","author":"O Ljunggren","year":"2014","unstructured":"Ljunggren O, Benhamou CL, Dekker J et al (2014) Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS). Curr Med Res Opin 30(8):1607\u20131616","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"77_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00223-016-0143-5","volume":"99","author":"BL Langdahl","year":"2016","unstructured":"Langdahl BL, Ljunggren O, Benhamou CL et al (2016) Fracture rate, quality of life and back pain in patients with osteoporosis treated with teriparatide: 24-month results from the Extended Forsteo Observational Study (ExFOS). Calcif Tissue Int 99(3):259\u2013271","journal-title":"Calcif Tissue Int"},{"key":"77_CR14","doi-asserted-by":"publisher","unstructured":"Napoli N, Langdahl BL, Ljunggren O et al (2018) Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo(R) Observational Study (ExFOS). Calcif Tissue Int 16. \n                    https:\/\/doi.org\/10.1007\/s00223-018-0437-x","DOI":"10.1007\/s00223-018-0437-x"},{"key":"77_CR15","doi-asserted-by":"crossref","unstructured":"Aloumanis K, Karras D, Drossinos V, Korelis E, Polydorakis A (2011) Fracture incidence, quality of life, and back pain during 18-months treatment with teriparatide in Greek postmenopausal women with osteoporosis: results from the European Forsteo Observational Study. J Osteoporos 510398","DOI":"10.4061\/2011\/510398"},{"issue":"4","key":"77_CR16","first-page":"454","volume":"29","author":"K Aloumanis","year":"2012","unstructured":"Aloumanis K, Drossinos V, Trikka D, Karras D (2012) The European Forsteo Observational Study (EFOS). 18-month follow-up of Greek women completing teriparatide treatment for osteoporosis. Archives of Hellenic. Medicine 29(4):454\u2013460 [Greek]","journal-title":"Medicine"},{"issue":"16","key":"77_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12891-015-0600-8","volume":"05","author":"K Aloumanis","year":"2015","unstructured":"Aloumanis K, Kapetanos G, Bartzis N, Drossinos V (2015) Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS). BMC Musculoskelet Disord 05(16):136","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"77_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R (1996) EuroQol: the current state of play. Health policy 37(1):53\u201372","journal-title":"Health policy"},{"key":"77_CR19","unstructured":"Aloumanis K, Drossinos V, Hondrelis J, Disch D (2018) Treatment outcomes after teriparatide use in Greece: country subanalysis of the EFOS and ExFOS combined Observational Studies WCO-IOF-ESCEO-2018 2018; abstr. P428. Osteoporos Int 29(1)"},{"issue":"9","key":"77_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1359\/JBMR.050501","volume":"20","author":"R Prince","year":"2005","unstructured":"Prince R, Sipos A, Hossain A et al (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20(9):1507\u20131513","journal-title":"J Bone Miner Res"},{"issue":"4","key":"77_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"Eastell R, Nickelsen T, Marin F et al (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24(4):726\u2013736","journal-title":"J Bone Miner Res"},{"issue":"8","key":"77_CR22","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1210\/jc.2008-2630","volume":"94","author":"BZ Leder","year":"2009","unstructured":"Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS (2009) Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 94(8):2915\u20132921","journal-title":"J Clin Endocrinol Metab"},{"key":"77_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","volume":"98","author":"BZ Leder","year":"2017","unstructured":"Leder BZ, Tsai JN, Jiang LA, Lee H (2017) Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-follow-up). Bone 98:54\u201358","journal-title":"Bone"},{"issue":"8","key":"77_CR24","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Zanchetta JR, Russo L et al (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporosis Int 23(8):2141\u20132150","journal-title":"Osteoporosis Int"},{"issue":"2","key":"77_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jocn.2009.06.013","volume":"17","author":"S Ohtori","year":"2010","unstructured":"Ohtori S, Akazawa T, Murata Y et al (2010) Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci 17(2):209\u2013213","journal-title":"J Clin Neurosci"}],"updated-by":[{"DOI":"10.1007\/s42000-019-00102-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000}}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s42000-018-0077-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-018-0077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-018-0077-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T15:07:05Z","timestamp":1600268825000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s42000-018-0077-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,14]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["77"],"URL":"https:\/\/doi.org\/10.1007\/s42000-018-0077-6","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,14]]},"assertion":[{"value":"20 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Unfortunately in the original publication, the affiliation of the author N. Papaioannou was incorrectly provided.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Unfortunately in the original publication, the affiliation of the author N. Papaioannou was incorrectly provided.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Unfortunately in the original publication, the affiliation of the author N. Papaioannou was incorrectly provided.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KA and VD are employees of Pharmaserve-Lilly SACI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}